Health
KEYTRUDA® (pembrolizumab) Plus Chemotherapy With or Without Bevacizumab Reduced Risk of Disease Progression or Death Versus Chemotherapy With or Without Bevacizumab in Certain Patients With Platinum-Resistant Recurrent Ovarian Cancer
RAHWAY, N.J., October 18, 2025--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during
About this update from Merck & Company, Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":480,"height":217,"url":"https://media.zenfs.com/en/business-wire.com/55f0efacfc9c2ab36a461db1272ce7fa"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/7aGBdyq9jpIwl1iQGtvi_A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTQzNDtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/55f0efacfc9c2ab36a461db1272ce7fa","width":480,"height":217}},"lazy":false},{"type":"text","content":"Results from the first and second interim analyses of the Phase 3 KEYNOTE-B96 trial were selected for presentation during a Presidential Symposium session at the European Society for Medical Oncology Congress 2025","length":213,"tagName":"p","attribs":{}},{"type":"text","content":"With these results, KEYNOTE-B96 is the first trial of an immune checkpoint inhibitor-based treatment regimen in platinum-resistant recurrent ovarian cancer to show statistically significant improvements in progression-free survival for all comers and overall survival for patients whose tumors express PD-L1 versus placebo plus chemotherapy with or without bevacizumab","length":368,"tagName":"p","attribs":{}},{"type":"text","content":"Based on these data, the U.S. FDA has accepted for priority review a new supplemental Biologics License Application (sBLA) for KEYTRUDA plus chemotherapy with or without bevacizumab for certain patients with platinum-resistant recurrent ovarian cancer","length":251,"tagName":"p","attribs":{}},{"type":"text","content":"RAHWAY, N.J., October 18, 2025--(BUSINESS WIRE)--Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced the first presentation of results from the pivotal Phase 3 KEYNOTE-B96 trial, also known as ENGOT-ov65, evaluating KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in combination with chemotherapy (paclitaxel) with or without bevacizumab for the treatment of patients with platinum-resistant recurrent ovarian cancer. These late-breaking data will be presented today during a Presidential Symposium session at the European Society for Medical Oncology (ESMO) Congress 2025 (Presentation #LBA3).","length":637,"tagName":"p"},{"type":"text","content":"At the first interim analysis, with a median study follow-up of 15.6 months, KEYTRUDA plus chemotherapy with or without bevacizumab ...